Patients with JAK2V617F had a higher phosphatidylserine exposure than CALR and triple-negative groups, which was correlated with more hypercoagulability and could possibly explain the higher thrombotic risk in the JAK2V617F group [29]. The gene discussed is CALR; the disease is thrombophilia.